Telethon Kids Institute

Aboriginal and Torres Strait Islander people must be at the centre, not the margins, of LGBTQIA+ plans and policies

Retrieved on: 
Wednesday, July 26, 2023
Telethon Kids Institute, Violence, Suicide, Policy, Marriage, Woman, Statistics, Research, Imprisonment, Gender variance, Human voice, Man, Grief, Human, Homophobia, Population, Risk, Colonialism, First Nations, Racism, Federation, Health, Trauma, Death, Mental health, SB, Pharmaceutical industry, Nursing, Whaling, Toy, Aborigine, Indigenous

Yet there is insufficient data about Aboriginal and Torres Strait Islander LGBTQIASB+ people and mental health.

Key Points: 
  • Yet there is insufficient data about Aboriginal and Torres Strait Islander LGBTQIASB+ people and mental health.
  • These are Aboriginal English terms used by Aboriginal and Torres Strait Islander transgender women and men.
  • Research suggests Aboriginal and Torres Strait Islander LGBTQIASB+ people are at much higher risk of suicide and suicide-related behaviours.

What did our report find?

    • Both Indigenous people and LGBTQIA+ people experience poorer health outcomes and higher rates of health-impacting behaviours.
    • The report also found that Aboriginal and Torres Strait Islander LGBTQIASB+-led research, policy, and services are urgently needed to improve mental health and health outcomes for this group.

There is very limited data on Indigenous LGBTQIASB+ people

    • Aboriginal and Torres Strait Islander people are primarily categorised as “male” and “female” in health research, rather than in terms of their gender.
    • Even when data is collected on these groups, non-binary sex and gender is often excluded or overlooked due to small sample sizes.
    • Data on Aboriginal and Torres Strait Islander LGBTQIASB+ people and suicide-related behaviour is also limited.
    • Read more:
      New research shows how Indigenous LGBTIQ+ people don't feel fully accepted by either community

The impact of racism and discrimination

    • Aboriginal and Torres Strait Islander LGBTQIASB+ people commonly report experiencing racism and discrimination not only in the wider community, but also within LGBTQIA+ communities.
    • Our research also demonstrates poor health outcomes and increased vulnerability to suicide are outcomes of racism, discrimination, marginalisation, homophobia and transphobia.
    • Colonialism is the root cause of discrimination and violence towards Aboriginal and Torres Strait Islander LGBTQIASB+ people.

Aboriginal and Torres Strait Islander LGBTQIASB+ communities at the forefront

    • Aboriginal and Torres Strait Islander LGBTQIASB+ people need to be able to design and steer research and policy making at every level.
    • Governments should invest in Aboriginal and Torres Strait Islander community-controlled health organisations to improve capacity to service our communities.

Nevisense for skin barrier evaluation included in large Australian birth cohort study

Retrieved on: 
Thursday, December 15, 2022
Joondalup Health Campus, Electrode, Food, Pregnancy, Comparison of multi-paradigm programming languages, Genetics, Area studies, Disease, Child, Parent, Diabetes, Asthma, Obesity, EIS, Telethon, Skin, Telethon Kids Institute, Dermatitis, Atopic dermatitis, Risk, Pharmaceutical industry

SciBase will supply Nevisense, Nevisense Go and electrodes to follow up to 1,000 of the 10,000 children included in the project.

Key Points: 
  • SciBase will supply Nevisense, Nevisense Go and electrodes to follow up to 1,000 of the 10,000 children included in the project.
  • Of key interest is the development and progression of atopic dermatitis and the project is intending to utilise the Nevisense system to assess skin integrity in this context.
  • Nevisense and EIS will follow the development of atopic dermatitis through measurements of the skin barrier in children.
  • The measurements will help us develop and improve our AI-algorithms even further with the goal of delivering better, personalized treatments.

Zelira Therapeutics Launches ZYRAYDI™ B2B Technology to Create Pharma-grade Cannabis Capsules & Tablets for Global Markets

Retrieved on: 
Tuesday, September 20, 2022
ASX, Tablet, Cannabinoid, FDA, Einstein Medical Center Philadelphia, Curtin University, Hospital, Zinc, Organization, Autism, OTCQB, Company, CHOP, Partnership, St. Vincent's Hospital, Therapy, Capsule, Telethon Kids Institute, GRAS, Excipient, Insomnia, OTC, CEO, Technology, Research, HOPE, University, The Non-GMO Project, Pharmaceutical industry, Generic drug, Black seed

PHILADELPHIA, Sept. 20, 2022 /PRNewswire/ -- Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the research, development and commercialization of clinically validated cannabinoid medicines, is pleased to announce the launch of ZYRAYDI™, its patented, licensable technology for the future of the medical cannabis industry.

Key Points: 
  • ZYRAYDI is a proprietary Enhanced Distillate Capture and Dissolution Matrix (EDCDM) technology that substantially traps the distillate in a free flow powder matrix and increases the rate of dissolution.
  • With ZYRAYDI, Zelira Therapeutics continues to create new, innovative ways to produce pharmaceutical-grade cannabinoid oral dosage forms like capsules and tablets.
  • Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) is a leading global therapeutic medical cannabinoid company with access to the world's largest and fastest growing cannabinoid medicine markets.
  • Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets.

Zelira's Zenivol™, the World's First Clinically Validated Cannabinoid Medication for Insomnia, Achieves Regulatory Approval in Germany

Retrieved on: 
Thursday, July 21, 2022
Zinc, Knowledge, St. Vincent's Hospital, University, Physician, Insomnia, Curtin University, HOPE, Research, OTC, Partnership, Pharmacy, Marketing, ASX, Hospital, Telethon Kids Institute, Autism, Organization, IMC, Einstein Medical Center Philadelphia, Journal, Company, Patient, OTCQB, Cannabinoid, CHOP, Pharmaceutical industry, EU, Black seed, Sleep

Zenivol is the world's first and only clinically validated, cannabis-based pharmaceutical sleep medication.

Key Points: 
  • Zenivol is the world's first and only clinically validated, cannabis-based pharmaceutical sleep medication.
  • Zenivol is the world's first and only clinically validated , pharmaceutical-grade, cannabis-based sleep medication.
  • Zenivol's clinical research achieved the highest level of scientific review when it was peer reviewed in the Journal of Sleep .
  • With formal regulatory approval for Zenivol now received in Germany, we continue to progress activities to license Zenivol into other global markets."

New Results Highlight Feasibility of Text Message Intervention to Encourage Dog-Facilitated Physical Activity

Retrieved on: 
Monday, June 13, 2022
Randomized controlled trial, Pediatrics, Caregiver, Parent, Text messaging, Research, Telethon Kids Institute, University of Western Australia, UWA, PAWS, Animal, BMC, Awareness, University, Outline, Preventive healthcare, Pediatric Research, Physical activity, MHealth, BioMed Central, Dog, Public health, Walking, Family, Screen time, Pharmaceutical industry, Hunting, Entertainment

WASHINGTON, June 13, 2022 /PRNewswire-PRWeb/ -- The Human Animal Bond Research Institute (HABRI) announced the results of a new publication led by researchers at the Telethon Kids Institute and The University of Western Australia (UWA), which found a simple health intervention using text messaging may encourage children to spend more time being physically active with their family dog. This randomized controlled trial was published in the journal BMC Pediatrics.

Key Points: 
  • "Interventions, policies, and community programs should capitalize on the high level of dog ownership and incorporate dog walking or play into physical activity campaigns."
  • "This study shows that a simple text message reminder to play or walk with the family dog can result in increased physical activity for children and their caregivers," said Steven Feldman, President of HABRI.
  • Dr. Christian and colleagues led the Play Spaces and Environments for Children's Physical Activity' (PLAYCE) PAWS mHealth intervention, a randomized controlled trial conducted in Perth, Western Australia.
  • A mobile health intervention to encourage physical activity in children: a randomised controlled trial.

Proactive news headlines including Mako Gold, Radiopharm Theranostics, Core Lithium and Stelar Metals

Retrieved on: 
Monday, June 6, 2022
Lithium, Memorandum of understanding, Copper, OTCQB, LOM, RAD, Nickel, NYSE, Gold, Engineering, QPM, Telethon Kids Institute, Silver, CXO, CGP, ASX, PAB, DFS, SLB, KOTH, IOCG, QML, MRE, Acquisition, Science, Yangon, Proactivity, KBR, GLOBE, Sempra Metals Ltd v IRC, Saindak Copper Gold Project, Rare-earth element, Mining, Callisto, Eastern Corridor Commuter Rail, Central Africa

Click here

Key Points: 
  • Click here
    Armada Metals Ltd (ASX:AMM) believes it has a wealth of nickel and copper beneath its feet in Gabon, an oceanside country in Central Africa that remains largely underexplored.
  • Click here
    Anson Resources Ltd (ASX:ASN) is working towards a major expansion in planned lithium production capacity of its core asset, the Paradox Lithium Project in Utah, USA, now targeting 10,000 tonnes annually of battery-grade lithium carbonate.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

Newly Published Study Shows Young Children with Pet Dogs Benefit from Greater Physical Activity and Reduced Screen Time

Retrieved on: 
Tuesday, March 29, 2022
University of Western Australia, Physical activity, Screen time, Preventive healthcare, Walking, Parent, Regional policy of the European Union, Research, Telethon Kids Institute, Actigraphy, Sleep, PETS, Health, Association, Dog, Observational study, UWA, Movement, Animal, University, Pharmaceutical industry, Toy

WASHINGTON , March 29, 2022  /PRNewswire-PRWeb/ -- The Human Animal Bond Research Institute (HABRI) has hailed the results of a HABRI-funded study led by researchers at the Telethon Kids Institute and The University of Western Australia (UWA) that found dog ownership to be positively associated with physical activity in preschool-aged children. The study was just published in the journal Preventive Medicine Reports.

Key Points: 
  • "With many young children not meeting the recommended levels of physical activity, screen time and sleep, we hope these results will help parents, children and pets be more active and healthy."
  • "With these new research findings, we have solid evidence that pet dogs can benefit physical health in young children," said Steven Feldman, President of HABRI.
  • The research team, led by Dr. Christian, analyzed data from 1,336 children aged 2-5 years in the 'Play Spaces and Environments for Children's Physical Activity' (PLAYCE) study, an observational study investigating the influence of the childcare environment on young children's physical activity.
  • Parent-report surveys collected information about socio-demographic characteristics, family dog ownership, physical activity, outdoor play, family dog walking and play, screen time and sleep.

PharmaJet Partner Technovalia Announces Interim Results of Needle-free COVID-19 Vaccine Trial

Retrieved on: 
Tuesday, February 15, 2022
Medical Devices, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, DPT vaccine, CEO, COVID, Use, Certification, BIOSCI, System, RNA, Review, Vaccine, RNA transfection, Injection, Infection, Safety, Technology, WHO, Telethon Kids Institute, LinkedIn, PQS, Partnership, Ageing, U.S. FDA, Research, DNA, COVID-19, News, Vaccination, CE marking, PharmaJet, Technovalia, BioNet, PHARMAJET, TECHNOVALIA, BIONET

PharmaJet , a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that their partner, Technovalia , has reported interim safety results from their needle-free SARS-CoV2 DNA vaccine phase 1 trial.

Key Points: 
  • PharmaJet , a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that their partner, Technovalia , has reported interim safety results from their needle-free SARS-CoV2 DNA vaccine phase 1 trial.
  • Interim safety data of COVIGEN, their DNA COVID-19 vaccine candidate, is well tolerated and no safety concerns were observed.
  • Mr. Laurent Dapremont, Chief Executive Officer of Technovalia said, We are pleased with these positive interim safety results from the ongoing COVALIA study which reinforce the existing pre-clinical data available.
  • These results are consistent with data from other DNA and RNA based vaccines administered using the PharmaJet Needle-free Injection Systems (NFIS).

Zelira™ Launches RAF FIVE™ Acne Treatment Products Through Its Dermatology Focused Subsidiary

Retrieved on: 
Thursday, September 23, 2021
Acne, Peptide, THC, Therapy, Clinical trial, Partnership, University, OTC, CHOP, RAF, Hospital, Cannabinoid, Curtin University, Patient, Cannabidiol, Insomnia, Einstein Medical Center Philadelphia, Bacteria, Dermatology, Zinc, Company, Psoriasis, ASX, Science, Cannabis, HOPE, Research, Telethon Kids Institute, Organization, Salicylic acid, Weizmann Institute of Science, Nicotinamide, Hyaluronic acid, Autism, St. Vincent's Hospital, Cosmetics, Pharmaceutical industry

The five-product RAF FIVE line consists of the Wash Away Gel Cleanser Acne Treatment, Spot On Acne Treatment, Kick Off Hydrating Lotion Broad Spectrum SPF 30 Sunscreen, After Hours Moisturizing Lotion Acne Treatment, and Clear the Way Acne Treatment Pads.

Key Points: 
  • The five-product RAF FIVE line consists of the Wash Away Gel Cleanser Acne Treatment, Spot On Acne Treatment, Kick Off Hydrating Lotion Broad Spectrum SPF 30 Sunscreen, After Hours Moisturizing Lotion Acne Treatment, and Clear the Way Acne Treatment Pads.
  • The RAF FIVE line is Zelira's first step into the acne medication market valued at more than US$11 billion worldwide.
  • Zelira Therapeutics CEO and Managing Director, Dr. Oludare Odumosu, commented, "I am excited to announce the launch of Zelira's Dermatology subsidiary and the RAF FIVE acne treatment line of skincare products.
  • We have a unique opportunity to present a differentiated suite of proven acne treatment solutions to the US$11 billion acne treatment market where there is a high level of dissatisfaction with existing products and unmet needs.